This is a randomized, partially double-blind trail for ACTG 302/303 participant who were originally randomized to d4T monotherapy or new combination nucleoside therapy and who remain on their originally assigned treatment at the time enrollment into this rollover protocol.
Showing the most recent 10 out of 1085 publications